{
  "meta": {
    "data_length": 1,
    "message": "Statements retrieved successfully",
    "request_url": "http://api.moalmanac.org/statements?agent_id=fda&proposition_id=383",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.035116,
    "timestamp_received": "2026-05-15T13:17:30.966470+00:00Z",
    "timestamp_returned": "2026-05-15T13:17:31.001586+00:00Z",
    "trace_id": "75bfb454-aa7b-4356-ab54-4642cf8eaedb"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-05-07"
  },
  "data": [
    {
      "id": 453,
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.",
      "contributions": [
        {
          "id": 0,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Initial access of FDA approvals",
          "date": "2024-10-30"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda.rituxan",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Rituxan (rituximab) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Genentech, Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Rituxan",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "rituximab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 103705,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2021-12-17",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:fda.rituxan:4",
        "indication": "RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.",
        "initial_approval_date": "2021-12-02",
        "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5465lbl.pdf",
        "description": "The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.",
        "raw_biomarkers": "CD20-positive",
        "raw_cancer_type": "mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)",
        "raw_therapeutics": "Rituxan (rituximab) in combination with chemotherapy",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:fda.rituxan",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Rituxan (rituximab) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Genentech, Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Rituxan",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "rituximab",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 103705,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2021-12-17",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 383,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 54,
            "name": "CD20 +",
            "genes": [],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Protein expression"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "marker",
                "value": "CD20"
              },
              {
                "name": "unit",
                "value": "status"
              },
              {
                "name": "equality",
                "value": "="
              },
              {
                "name": "value",
                "value": "Positive"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 77,
          "conceptType": "Disease",
          "name": "Diffuse Large B-Cell Lymphoma",
          "primaryCoding": {
            "id": "oncotree:DLBCLNOS",
            "code": "DLBCLNOS",
            "name": "Diffuse Large B-Cell Lymphoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=DLBCLNOS"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 82,
          "membership_operator": "AND",
          "therapies": [
            {
              "id": 122,
              "conceptType": "Drug",
              "name": "Prednisone",
              "primaryCoding": {
                "id": "ncit:C770",
                "code": "C770",
                "name": "Prednisone",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:8640",
                    "code": "8640",
                    "name": "prednisone",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=8640"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1551099",
                    "code": "1551099",
                    "name": "prednisone",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1551099"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:116602009",
                    "code": "116602009",
                    "name": "Prednisone",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=116602009&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4023242",
                    "code": "4023242",
                    "name": "Prednisone",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4023242"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Corticosteroid"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 61,
              "conceptType": "Drug",
              "name": "Vincristine",
              "primaryCoding": {
                "id": "ncit:C933",
                "code": "C933",
                "name": "Vincristine",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:11202",
                    "code": "11202",
                    "name": "vincristine",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=11202"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1308290",
                    "code": "1308290",
                    "name": "vincristine",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1308290"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:387126006",
                    "code": "387126006",
                    "name": "Vincristine",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=387126006&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4304296",
                    "code": "4304296",
                    "name": "Vincristine",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4304296"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Vinca alkaloid chemotherapy"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 59,
              "conceptType": "Drug",
              "name": "Cyclophosphamide",
              "primaryCoding": {
                "id": "ncit:C405",
                "code": "C405",
                "name": "Cyclophosphamide",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:3002",
                    "code": "3002",
                    "name": "cyclophosphamide",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3002"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1310317",
                    "code": "1310317",
                    "name": "cyclophosphamide",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1310317"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:387420009",
                    "code": "387420009",
                    "name": "Cyclophosphamide",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=387420009&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4299054",
                    "code": "4299054",
                    "name": "Cyclophosphamide",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4299054"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Alkylating chemotherapy"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 2,
              "conceptType": "Drug",
              "name": "Doxorubicin",
              "primaryCoding": {
                "id": "ncit:C456",
                "code": "C456",
                "name": "Doxorubicin",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:3639",
                    "code": "3639",
                    "name": "doxorubicin",
                    "system": "RxNorm",
                    "systemVersion": "20250602",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3639"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4187583",
                    "code": "4187583",
                    "name": "Doxorubicin",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4187583"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:372817009",
                    "code": "372817009",
                    "name": "Doxorubicin",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=372817009&edition=MAIN/2026-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1338512",
                    "code": "1338512",
                    "name": "doxorubicin",
                    "system": "OMOP",
                    "systemVersion": "v20250827",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1338512"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "Topoisomerase inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Chemotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            },
            {
              "id": 60,
              "conceptType": "Drug",
              "name": "Rituximab",
              "primaryCoding": {
                "id": "ncit:C1702",
                "code": "C1702",
                "name": "Rituximab",
                "system": "https://evsexplore.semantics.cancer.gov",
                "systemVersion": "25.01d",
                "iris": [
                  "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702"
                ]
              },
              "mappings": [
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "rxcui:121191",
                    "code": "121191",
                    "name": "rituximab",
                    "system": "RxNorm",
                    "systemVersion": "02-Mar-2026",
                    "iris": [
                      "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=121191"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:1314273",
                    "code": "1314273",
                    "name": "rituximab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/1314273"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "sctid:386919002",
                    "code": "386919002",
                    "name": "Rituximab",
                    "system": "SNOMED",
                    "systemVersion": "2025-03-01",
                    "iris": [
                      "https://browser.ihtsdotools.org/?perspective=full&conceptId1=386919002&edition=MAIN/2025-03-01&release=&languages=en"
                    ]
                  }
                },
                {
                  "relation": "relatedMatch",
                  "coding": {
                    "id": "omop:4299850",
                    "code": "4299850",
                    "name": "Rituximab",
                    "system": "OMOP",
                    "systemVersion": "v20260227",
                    "iris": [
                      "https://athena.ohdsi.org/search-terms/terms/4299850"
                    ]
                  }
                }
              ],
              "extensions": [
                {
                  "name": "therapy_strategy",
                  "value": [
                    "CD20 inhibition"
                  ],
                  "description": "Associated therapeutic strategy or mechanism of action of the therapy."
                },
                {
                  "name": "therapy_type",
                  "value": "Immunotherapy",
                  "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
                }
              ]
            }
          ]
        }
      }
    }
  ]
}